Artwork

Content provided by Rheumatology News International and Rhnews@elsevier.com (Rheumatology News International). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Rheumatology News International and Rhnews@elsevier.com (Rheumatology News International) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 2: Establishing the Evidence: Clinical Trials with TNF Inhibitors

14:53
 
Share
 

Manage episode 156760069 series 1199499
Content provided by Rheumatology News International and Rhnews@elsevier.com (Rheumatology News International). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Rheumatology News International and Rhnews@elsevier.com (Rheumatology News International) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Professor Smolen discusses the evidence supporting the ability of TNF-alpha agents to result in substantial and sustained improvement in symptoms of psoriatic arthritis. Agents including infliximab and etanercept result in not only clinical improvement but also slow the radiographic progression of joint disease and damage. Further, the combination therapy of a TNF-alpha agent and methotrexate results in highly significant improvement in arthritic symptoms and signs.
  continue reading

6 episodes

Artwork
iconShare
 
Manage episode 156760069 series 1199499
Content provided by Rheumatology News International and Rhnews@elsevier.com (Rheumatology News International). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Rheumatology News International and Rhnews@elsevier.com (Rheumatology News International) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Professor Smolen discusses the evidence supporting the ability of TNF-alpha agents to result in substantial and sustained improvement in symptoms of psoriatic arthritis. Agents including infliximab and etanercept result in not only clinical improvement but also slow the radiographic progression of joint disease and damage. Further, the combination therapy of a TNF-alpha agent and methotrexate results in highly significant improvement in arthritic symptoms and signs.
  continue reading

6 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide